Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of "Buy" from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $12.56.

CATX has been the topic of a number of research reports. Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their price objective for the stock from $15.00 to $16.00 in a research note on Tuesday, June 3rd. Truist Financial cut their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. B. Riley reiterated a "buy" rating and issued a $12.00 price objective (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Perspective Therapeutics in a report on Monday, March 31st. Finally, Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Monday, June 23rd.

Perspective Therapeutics Trading Down 3.2%

NYSE:CATX opened at $3.98 on Friday. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $16.55. The company's fifty day moving average price is $3.08 and its 200-day moving average price is $2.87.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Bank of New York Mellon Corp lifted its holdings in Perspective Therapeutics by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock valued at $458,000 after purchasing an additional 4,693 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new position in Perspective Therapeutics during the fourth quarter valued at $160,000. HighTower Advisors LLC lifted its holdings in Perspective Therapeutics by 26.1% during the fourth quarter. HighTower Advisors LLC now owns 178,111 shares of the company's stock valued at $568,000 after purchasing an additional 36,875 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Perspective Therapeutics during the fourth quarter valued at $79,000. Finally, JPMorgan Chase & Co. lifted its holdings in Perspective Therapeutics by 498.3% during the fourth quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock valued at $475,000 after purchasing an additional 124,133 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.